In this episode, AGG Life Sciences co-chairs Alan Minsk and Gabe Scannapieco unpack recent developments at the U.S. Department of Justice that could reshape regulatory risk for life sciences organizations.
They discuss the disbanding of DOJ’s Consumer Protection Branch (“CPB”) and what the loss of centralized oversight could mean for coordinated investigations in the industry. The conversation also examines DOJ’s intensified focus on counterfeit drugs and its targeting of the entire supply chain in See more +
In this episode, AGG Life Sciences co-chairs Alan Minsk and Gabe Scannapieco unpack recent developments at the U.S. Department of Justice that could reshape regulatory risk for life sciences organizations.
They discuss the disbanding of DOJ’s Consumer Protection Branch (“CPB”) and what the loss of centralized oversight could mean for coordinated investigations in the industry. The conversation also examines DOJ’s intensified focus on counterfeit drugs and its targeting of the entire supply chain in collaboration with FDA, DEA, and other agencies.
Drawing on Gabe’s experience as a former assistant director at the CPB and the firm’s extensive regulatory services, this episode provides practical insights for companies looking to stay ahead of shifting enforcement priorities. See less -
